A rare case of Cotrimoxazole induced acute pancreatitis, acute kidney injury and crystalluria (APAKIC)

Sadhana Holla, Balaji Ommurugan, D. Amita, K. L. Bairy, K. Saravu, Jagadesh Madireddi

Research output: Contribution to journalArticle

Abstract

Cotrimoxazole (TMP/SMX) is the drug of choice for treating Pneumocystis Jeroveci pneumonia (PJP) in retroviral infections. Incidence of Co-trimoxazole causing pancreatitis and kidney injury being extremely rare, adverse drug reaction (ADR) monitoring is warranted. A 50 year old female newly diagnosed patient with HIV1 positive was treated with TMP/SMX for pneumocystis pneumonia. A total of 3 tablets each containing 800mg sulfamethoxazole and 160 mg trimethoprim thrice daily for 24 days along with intravenous injection once daily for 6 days was given. Three adverse drug reports were reported. Rise in serum amylase/lipase suggesting acute pancreatitis and rise in urea, creatinine and electrolytes suggesting acute kidney injury was observed along with crystalluria. As a part of intervention the drug was stopped, 5% dextrose along with sodium bicarbonate were given. Kidney injury and crystalluria resolved, pancreatitis is still resolving. All ADRs were classified as probable according to Naranjo scale, moderately severe according to Hartwig's scale. The kidney injury is preventable and acute pancreatitis and crystalluria are not preventable according to Schumock and Thornton scale. This case demonstrates a causal relationship between TMP/SMX and above mentioned adverse events. Hence, it is prudent enough to exercise caution when using Cotrimoxazole.

Original languageEnglish
Pages (from-to)1099-1102
Number of pages4
JournalResearch Journal of Pharmaceutical, Biological and Chemical Sciences
Volume7
Issue number1
Publication statusPublished - 01-01-2016

Fingerprint

Sulfamethoxazole Drug Combination Trimethoprim
Acute Kidney Injury
Pancreatitis
Pneumocystis Pneumonia
Kidney
Pharmaceutical Preparations
Wounds and Injuries
Sulfamethoxazole
Trimethoprim
Sodium Bicarbonate
Drug Monitoring
Amylases
Drug-Related Side Effects and Adverse Reactions
Lipase
Intravenous Injections
Electrolytes
Tablets
Urea
Creatinine
Exercise

All Science Journal Classification (ASJC) codes

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Holla, Sadhana ; Ommurugan, Balaji ; Amita, D. ; Bairy, K. L. ; Saravu, K. ; Madireddi, Jagadesh. / A rare case of Cotrimoxazole induced acute pancreatitis, acute kidney injury and crystalluria (APAKIC). In: Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2016 ; Vol. 7, No. 1. pp. 1099-1102.
@article{dee2066cc0d34096b2469c662f4c20f1,
title = "A rare case of Cotrimoxazole induced acute pancreatitis, acute kidney injury and crystalluria (APAKIC)",
abstract = "Cotrimoxazole (TMP/SMX) is the drug of choice for treating Pneumocystis Jeroveci pneumonia (PJP) in retroviral infections. Incidence of Co-trimoxazole causing pancreatitis and kidney injury being extremely rare, adverse drug reaction (ADR) monitoring is warranted. A 50 year old female newly diagnosed patient with HIV1 positive was treated with TMP/SMX for pneumocystis pneumonia. A total of 3 tablets each containing 800mg sulfamethoxazole and 160 mg trimethoprim thrice daily for 24 days along with intravenous injection once daily for 6 days was given. Three adverse drug reports were reported. Rise in serum amylase/lipase suggesting acute pancreatitis and rise in urea, creatinine and electrolytes suggesting acute kidney injury was observed along with crystalluria. As a part of intervention the drug was stopped, 5{\%} dextrose along with sodium bicarbonate were given. Kidney injury and crystalluria resolved, pancreatitis is still resolving. All ADRs were classified as probable according to Naranjo scale, moderately severe according to Hartwig's scale. The kidney injury is preventable and acute pancreatitis and crystalluria are not preventable according to Schumock and Thornton scale. This case demonstrates a causal relationship between TMP/SMX and above mentioned adverse events. Hence, it is prudent enough to exercise caution when using Cotrimoxazole.",
author = "Sadhana Holla and Balaji Ommurugan and D. Amita and Bairy, {K. L.} and K. Saravu and Jagadesh Madireddi",
year = "2016",
month = "1",
day = "1",
language = "English",
volume = "7",
pages = "1099--1102",
journal = "Research Journal of Pharmaceutical, Biological and Chemical Sciences",
issn = "0975-8585",
publisher = "RJPBCS",
number = "1",

}

A rare case of Cotrimoxazole induced acute pancreatitis, acute kidney injury and crystalluria (APAKIC). / Holla, Sadhana; Ommurugan, Balaji; Amita, D.; Bairy, K. L.; Saravu, K.; Madireddi, Jagadesh.

In: Research Journal of Pharmaceutical, Biological and Chemical Sciences, Vol. 7, No. 1, 01.01.2016, p. 1099-1102.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A rare case of Cotrimoxazole induced acute pancreatitis, acute kidney injury and crystalluria (APAKIC)

AU - Holla, Sadhana

AU - Ommurugan, Balaji

AU - Amita, D.

AU - Bairy, K. L.

AU - Saravu, K.

AU - Madireddi, Jagadesh

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Cotrimoxazole (TMP/SMX) is the drug of choice for treating Pneumocystis Jeroveci pneumonia (PJP) in retroviral infections. Incidence of Co-trimoxazole causing pancreatitis and kidney injury being extremely rare, adverse drug reaction (ADR) monitoring is warranted. A 50 year old female newly diagnosed patient with HIV1 positive was treated with TMP/SMX for pneumocystis pneumonia. A total of 3 tablets each containing 800mg sulfamethoxazole and 160 mg trimethoprim thrice daily for 24 days along with intravenous injection once daily for 6 days was given. Three adverse drug reports were reported. Rise in serum amylase/lipase suggesting acute pancreatitis and rise in urea, creatinine and electrolytes suggesting acute kidney injury was observed along with crystalluria. As a part of intervention the drug was stopped, 5% dextrose along with sodium bicarbonate were given. Kidney injury and crystalluria resolved, pancreatitis is still resolving. All ADRs were classified as probable according to Naranjo scale, moderately severe according to Hartwig's scale. The kidney injury is preventable and acute pancreatitis and crystalluria are not preventable according to Schumock and Thornton scale. This case demonstrates a causal relationship between TMP/SMX and above mentioned adverse events. Hence, it is prudent enough to exercise caution when using Cotrimoxazole.

AB - Cotrimoxazole (TMP/SMX) is the drug of choice for treating Pneumocystis Jeroveci pneumonia (PJP) in retroviral infections. Incidence of Co-trimoxazole causing pancreatitis and kidney injury being extremely rare, adverse drug reaction (ADR) monitoring is warranted. A 50 year old female newly diagnosed patient with HIV1 positive was treated with TMP/SMX for pneumocystis pneumonia. A total of 3 tablets each containing 800mg sulfamethoxazole and 160 mg trimethoprim thrice daily for 24 days along with intravenous injection once daily for 6 days was given. Three adverse drug reports were reported. Rise in serum amylase/lipase suggesting acute pancreatitis and rise in urea, creatinine and electrolytes suggesting acute kidney injury was observed along with crystalluria. As a part of intervention the drug was stopped, 5% dextrose along with sodium bicarbonate were given. Kidney injury and crystalluria resolved, pancreatitis is still resolving. All ADRs were classified as probable according to Naranjo scale, moderately severe according to Hartwig's scale. The kidney injury is preventable and acute pancreatitis and crystalluria are not preventable according to Schumock and Thornton scale. This case demonstrates a causal relationship between TMP/SMX and above mentioned adverse events. Hence, it is prudent enough to exercise caution when using Cotrimoxazole.

UR - http://www.scopus.com/inward/record.url?scp=84955250271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955250271&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 1099

EP - 1102

JO - Research Journal of Pharmaceutical, Biological and Chemical Sciences

JF - Research Journal of Pharmaceutical, Biological and Chemical Sciences

SN - 0975-8585

IS - 1

ER -